
Keywords: L-dopa، levodopa; PD, Parkinson’s disease; DAergic, dopaminergic; SNpc, substantia nigra pars compacta; DA, dopamine; LB, lewy body; α-syn, alpha synuclein; L-DOPA, levodopa; MAO, monoamine oxidase; CNS, central nervous system; DDS, drug delivery systems; MPs, microparticl